Keywords
Judge Decisions
Right to Health
DOI:
https://doi.org/10.17566/ciads.v6i2.387How to Cite
Abstract
Objective To analyze Federal expenditures for the Brazilian public health system with drugs obtained through lawsuits between the years 2011-2014. Methods: cross-sectional study, with descriptive and analytical characteristics. Data collected from the DW / COMPRASNET platform. Results: In total 12,578 lawsuits were identified at the federal level and 15 drugs with the highest acquisition value were extracted. Of these, seven drugs corresponded to US$ 452.644.065.68 million dollars of the federal budget, which represented 87% of the total expenditure of the actions studied. Of the 15 drugs / year studied, 14.28% (n = 4) were registered at the National Brazilian Surveillance Agency (ANVISA), were incorporated by the National Commission for the Incorporation of Technologies in SUS (CONITEC) and were part of the List of essential drugs (RENAME); 46.42% (n = 13) were registered with ANVISA, but not incorporated by CONITEC and not members of RENAME; 3.57% (n = 1) registered in ANVISA, incorporated by CONITEC and non-RENAME members and 35.71% (n = 10) without ANVISA registration, not incorporated by CONITEC and not RENAME members. Conclusion: With the Lawsuits to receive free medication, the acquisitions are carried out without planning or establishing minimum criteria, may compromise SUS sustainability.References
Medici AC. Judicialização , integralidade e financiamento da saúde. Med Baseada em Evidências. 2010;15(2):81–7.
Soares JCR de S, Deprá AS. Ligações perigosas: Indústria farmacêutica, associações de pacientes e as batalhas judiciais por acesso a medicamentos. Physis. 2012;22(1):311–29.
Campello, Bernadete Santos, Beatriz Valadares Cendón and JMK. Fontes de informação para pesquisadores e profissionais. Belo Horizonte: Editora UFMG; 2007.
Marçal K. A Judicialização da Assistência Farmacêutica: o caso Pernambuco em 2009 e 2010. 2012 [cited 2017 May 30]; Available from: http://www.cpqam.fiocruz.br/bibpdf/2012marcal-kks.pdf
D’Espíndula T. Judicialização da medicina no acesso a medicamentos: reflexões bioéticas. Rev bioét(Impr) [Internet]. 2013 [cited 2017 May 30]; Available from: http://pesquisa.bvsalud.org/oncologiauy/resource/en/lil-704222
Sant’Ana J, Pepe V, Osorio-de-Castro C. Essencialidade e assistência farmacêutica: considerações sobre o acesso a medicamentos mediante ações judiciais no Brasil. 2011 [cited 2017 May 30]; Available from: http://iris.paho.org/xmlui/handle/123456789/9561
Mazza F. Os impasses entre a judicialização da saúde e o processo orçamentário sob a responsabilidade fiscal: uma análise dos fundamentos decisórios do Supremo Tribunal. 2013 [cited 2017 May 30]; Available from: http://pesquisa.bvsalud.org/enfermeria/resource/es/lil-713153
Conselho Nacional de Justiça. Atos Normativos. Recomendacao no 31. 2010. p. 4.
Palmeira G. Tribunal de contas da união [Internet]. Available from: file:///C:/Users/User/Documents/Artigo Karina/002.142.2015-5 _FiscSaude_.pdf
União ADA, Jurídica C, Ao J, Da M. ADVOCACIA-GERAL DA UNIÃO. 2012;
Authors and coauthors retain copyright but license the right of first publication to the Iberoamerican Journal of Health Law.
The Journal has been using CC Attribution 4.0 International (CC BY 4.0) since January 2023. This license allows the user to share and adapt the work, but they must give the appropriate credit to authors and coauthors and mention the Iberoamerican Journal of Health Law. The license Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International was used until 2022.